18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer.

Christos Sachpekidis, Ali Afshar-Oromieh, K Kopka, D S Strauss, L Pan, U Haberkorn & A Dimitrakopoulou-Strauss
OBJECTIVES Aim of the present analysis is to investigate the biodistribution and pharmacokinetics of the recently clinically introduced radioligand 18F-PSMA-1007 in patients with biochemical recurrence or progression of prostate cancer (PC) by means of multiparametric (dynamic and whole-body) PET/CT. METHODS Twenty-five (25) patients with PC biochemical relapse or progression (median age = 66.0 years) were enrolled in the analysis. The median PSA value was 1.2 ng/mL (range = 0.1-237.3 ng/mL) and the median Gleason score...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.